Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial

This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally-advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-12-12
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2807
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial

Haresh Naringrekar, Athanassios Argiris, Eric V. Mastrolonardo, Joseph Curry et al.
Clinical Cancer Research
Head and Neck Cancer Studies
article

Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial

Haresh Naringrekar, Athanassios Argiris, Eric V. Mastrolonardo, Joseph Curry, Adam Luginbuhl, Stacey Gargano, Voichita Bar‐Ad, Richard Andrew Goldman, Andrew Yampolsky, Benjamin E. Leiby, Christopher Fundakowski, Madalina Tuluc, Pablo Llerena, Zachary Elliott, Dawn Poller, Jennifer M. Johnson, Charalambos Solomides, David M. Cognetti, Larry A. Harshyne, Ralph Zinner, Kathryn Nunes, Rita Axelrod
article en

Abstract

This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally-advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN.

Clinical Cancer Research
University of North Carolina at Chapel Hill (US), University of Kentucky (US), Thomas Jefferson University (US), Thomas Jefferson University Hospital (US), Markey Cancer Center (US), Sidney Kimmel Cancer Center (US)
Openalex Percentile: Top 44%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.